Open AccessTamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Author(s) -
Daniel L. Hertz,
Allison M. Deal,
Joseph G. Ibrahim,
Christine M. Walko,
Karen E. Weck,
Sandra D. Anderson,
Gustav Magrinat,
Oludamilola Olajide,
Susan Moore,
R. Raab,
Daniel R. Carrizosa,
Steven Corso,
Garry Schwartz,
Mark Graham,
Jeffrey Peppercorn,
David R. Jones,
Zeruesenay Desta,
David A. Flockhart,
James P. Evans,
Howard L. McLeod,
Lisa A. Carey,
William Irvin
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/ymhw-r398
Subject(s) - tamoxifen , cyp2d6 , toxicity , medicine , pharmacology , oncology , cancer , breast cancer , metabolism , cytochrome p450